Literature DB >> 16467082

ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.

Marta Crespo1, Neus Villamor, Eva Giné, Ana Muntañola, Dolors Colomer, Teresa Marafioti, Margaret Jones, Mireia Camós, Elias Campo, Emili Montserrat, Francesc Bosch.   

Abstract

PURPOSE: The ZAP-70 gene is normally expressed in T and natural killer cells, where it is required for the T-cell receptor (TCR) signaling. More recently, it has been described that ZAP-70 contributes to the B-cell development at early stages of B-cell differentiation in mice. The purpose was to investigate the presence of ZAP-70 in normal pro/pre B cells and mature B cells and in tumoral cells from B-acute lymphoblastic leukemias (B-ALL). EXPERIMENTAL
DESIGN: ZAP-70 expression was ascertained by flow cytometry, immunofluorescence, Western blot, and quantitative reverse transcription-PCR. Analysis of ZAP-70 and other signaling proteins of the pre-TCR/TCR was done by Western blot.
RESULTS: ZAP-70 was expressed in pro/pre B cells but not in normal mature B cells derived from bone marrow, peripheral blood, or tonsil. Among tumoral cells, ZAP-70 was expressed in 56% of B-ALLs with pro/pre B-cell phenotype and in 4 of 6 Burkitt/ALL lymphomas. In B-ALL cells, expression of CD38 protein correlated with ZAP-70 expression (P = 0.05). Mutational analysis of the ZAP-70 gene revealed the absence of mutations in cases lacking ZAP-70 expression. Moreover, other elements of the pre-TCR/TCR signaling pathway, like LAT and Lck, were also found in B-ALL cells.
CONCLUSIONS: Among normal B-cell subsets, ZAP-70 was found expressed in normal pro/pre B cells but not in a significant proportion of normal B cells with mature phenotype. Moreover, the presence of ZAP-70 in B-ALLs probably reflects their cellular origin. The lack of ZAP-70 expression in normal mature B cells suggests that its expression in mature-derived neoplasms with different cellular origin, such as Burkitt's lymphoma and chronic lymphocytic leukemia, might be due to an aberrant phenomenon.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467082     DOI: 10.1158/1078-0432.CCR-05-1531

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  Prognostic factors in chronic lymphocytic leukemia.

Authors:  Neil E Kay; Tait D Shanafelt
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 3.952

2.  LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.

Authors:  Hatice Duzkale; Carmen D Schweighofer; Kevin R Coombes; Lynn L Barron; Alessandra Ferrajoli; Susan O'Brien; William G Wierda; John Pfeifer; Tadeusz Majewski; Bogdan A Czerniak; Jeffrey L Jorgensen; L Jeffrey Medeiros; Emil J Freireich; Michael J Keating; Lynne V Abruzzo
Journal:  Blood       Date:  2011-02-10       Impact factor: 22.113

3.  Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.

Authors:  Teresa Sadras; Mickaël Martin; Kohei Kume; Mark E Robinson; Supraja Saravanakumar; Gal Lenz; Zhengshan Chen; Joo Y Song; Tanya Siddiqi; Laura Oksa; Anne Marie Knapp; Jevon Cutler; Kadriye Nehir Cosgun; Lars Klemm; Veronika Ecker; Janet Winchester; Dana Ghergus; Pauline Soulas-Sprauel; Friedemann Kiefer; Nora Heisterkamp; Akhilesh Pandey; Vu Ngo; Lili Wang; Hassan Jumaa; Maike Buchner; Jürgen Ruland; Wing-Chung Chan; Eric Meffre; Thierry Martin; Markus Müschen
Journal:  Mol Cell       Date:  2021-04-19       Impact factor: 17.970

4.  Analysis of ZAP70 expression in adult acute lymphoblastic leukaemia by real time quantitative PCR.

Authors:  Geothy Chakupurakal; Andrew Bell; Mike Griffiths; Farooq Wandroo; Paul Moss
Journal:  Mol Cytogenet       Date:  2012-05-01       Impact factor: 2.009

5.  Activation of the signaling cascade in response to T lymphocyte receptor stimulation and prostanoids in a case of cutaneous lupus.

Authors:  Ana Maria Abreu-Velez; Graham Smith; Michael S Howard
Journal:  N Am J Med Sci       Date:  2011-05

6.  MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.

Authors:  K Vargova; M Pesta; P Obrtlikova; N Dusilkova; L Minarik; J Vargova; A Berkova; Z Zemanova; K Michalova; M Spacek; M Trneny; T Stopka
Journal:  Blood Cancer J       Date:  2017-07-21       Impact factor: 11.037

7.  Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia.

Authors:  Yu-Jie Wu; Hui Wang; Jian-Hua Liang; Yi Miao; Lu Liu; Hai-Rong Qiu; Chun Qiao; Rong Wang; Jian-Yong Li
Journal:  Onco Targets Ther       Date:  2016-02-18       Impact factor: 4.147

Review 8.  ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.

Authors:  Jingyu Chen; Andrew Moore; Ingo Ringshausen
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.